Sanofi India
- Market cap
- ₹ 6,379 Cr.
- P/E
- 15.6x
- P/B
- 8.7x
- 52-week range
- 2,758.2 – 4,898
- ROE
- 43%
- ROCE
- 58%
- Dividend yield
- 4.3%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sanofi India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)15.6 against a typical 34.6: cheaper than most peers (1st = cheapest).38th of 220
- Sales growth+7.9% against a typical +15.6% from a year earlier.122nd of 197
- Profit growth+20% against a typical +18.9% from a year earlier.79th of 160
- Share price, 3 months−12.3% against a typical −0.5%.157th of 200
- Size₹ 6,379.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).51st of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Dividend | Board Meeting Intimation for Consideration and Approval of the Unaudited Financial Results for the Quarter and Nine Months ended 30th September 2026; and Declaration and Approval of Interim Dividend, if any, for the Financial Year 2026. |
| 4 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 28 Apr 2026 | Financial Results | To consider and approve the unaudited financial results for the period ended March 31, 2026 |
| 25 Feb 2026 | Financial Results/Dividend | To consider and approve the Audited Financial Results and Statements for the Quarter and Financial Year ended 31st December 2025 and Recommendation of Final Dividend, if any. |
| 29 Oct 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 31 Jul 2025 | Financial Results | Board Meeting Intimation for consideration and approval of the Unaudited Financial Statements for the quarter and half-year ended 30th June 2025 |
| 14 May 2025 | Financial Results | The meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 14th May 2025, inter-alia to consider and approve the Unaudited Financial Statements for the Quarter ended 31st March 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 | 420 | 472 | 438 |
| Expenses | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 | 330 | 330 | 322 |
| Operating Profit | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 | 90 | 143 | 115 |
| OPM % | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% | 22% | 30% | 26% |
| Other Income | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | −22 | 3 | 4 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 | 10 | 9 | 9 |
| Profit before tax | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 | 83 | 138 | 112 |
| Tax % | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% | 26% | 26% | 26% |
| Net Profit | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 | 62 | 103 | 84 |
| EPS in Rs | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.7 | 51.96 | 30.22 | 33.04 | 26.83 | 44.61 | 36.3 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −2%
- 5 Years
- −9%
- 3 Years
- −13%
- TTM
- −9%
- 10 Years
- 3%
- 5 Years
- −7%
- 3 Years
- −13%
- TTM
- −4%
- 10 Years
- 2%
- 5 Years
- −9%
- 3 Years
- −9%
- TTM
- —
- 10 Years
- 26%
- 5 Years
- 37%
- 3 Years
- 48%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sanofi India | ₹ 2,998.30 | ₹ 6,379 Cr. | 15.6x | 8.7x | 43% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Rachid Ayari
- Chief Financial Officer, Whole Time Director
- Haresh Bachubhai Vala
- Compliance Officer, Company Secretary
- Deepak Arora
- Managing Director, Director
- Sudipta Chakraborty
- Additional Whole-time Director
- Mahadev Gawade
- Whole-Time Director and Site Director-Goa
- Bratin Bag
- Senior Director - Ethics and Business Integrity, South Asia
- Richa Bakshi
- People Excellence Lead
- Arvind Gadekar
- Medical Lead - International Pharma SE Asia & India
Prices are delayed and for information only. Nothing on this page is investment advice.